Genetically engineered biological agents in therapy for systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a prototype for chronic autoimmune disease. Its prevalence is 20 to 70 cases per 100,000 women and varies by race and ethnicity. Despite considerable progress in traditional therapy, many problems associated with the management of these patients need to be immed...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Elena Aleksandrovna Aseeva, S K Solovyev, E L Nasonov
Médium:	Artigo
Jazyk:	Russo
Vydáno:	IMA-PRESS LLC 2013-10-01
Edice:	Современная ревматология
Témata:	systemic lupus erythematosus diagnosis treatment genetically engineered biological agents belimumab
On-line přístup:	https://mrj.ima-press.net/mrj/article/view/493
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!